Document Detail

Gonadotropin-releasing hormone agonist to induce final oocyte maturation prevents the development of ovarian hyperstimulation syndrome in high-risk patients and leads to improved clinical outcomes compared with coasting.
MedLine Citation:
PMID:  20074722     Owner:  NLM     Status:  MEDLINE    
Ninety-four women undergoing IVF with peak E2 level>4000 pg/mL received leuprolide acetate (LA) trigger (LA trigger group) or had gonadotropins withheld for one or more days (coasting group) followed by hCG trigger, unless cycle cancellation occurred. There were no cases of ovarian hyperstimulation syndrome in either group, and the LA trigger group had significantly more oocytes retrieved (26.9+/-9.5 vs. 17.7+/-9.3) P<0.001, more normally fertilized oocytes (15.0+/-7.8 vs. 10.3+/-6.3) P=0.01, and higher clinical and ongoing pregnancy rates than the coasting group (52.5% vs. 27.2%; 49.2% vs. 24.2%, P=0.02 for both comparisons, respectively).
Andrea J DiLuigi; Lawrence Engmann; David W Schmidt; Donald B Maier; John C Nulsen; Claudio A Benadiva
Publication Detail:
Type:  Evaluation Studies; Journal Article     Date:  2010-01-13
Journal Detail:
Title:  Fertility and sterility     Volume:  94     ISSN:  1556-5653     ISO Abbreviation:  Fertil. Steril.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-30     Completed Date:  2010-09-01     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372772     Medline TA:  Fertil Steril     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1111-4     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
The Center for Advanced Reproductive Services, Division of Reproductive Endocrinology and Infertility, University of Connecticut Health Center, Farmington, Connecticut 06030-6224, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Drug Administration Schedule
Estradiol / blood
Fertility Agents, Female / administration & dosage,  adverse effects,  pharmacology
Gonadotropin-Releasing Hormone / agonists
Leuprolide / administration & dosage*,  adverse effects,  pharmacology*
Oocytes / drug effects*,  physiology
Oogenesis / drug effects
Ovarian Hyperstimulation Syndrome / blood,  etiology,  prevention & control*
Pregnancy Rate
Retrospective Studies
Risk Factors
Treatment Outcome
Withholding Treatment*
Reg. No./Substance:
0/Fertility Agents, Female; 33515-09-2/Gonadotropin-Releasing Hormone; 50-28-2/Estradiol; 53714-56-0/Leuprolide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The role of the left anterior temporal lobe in language processing revisited: Evidence from an indiv...
Next Document:  Markers of growth and development in primate primordial follicles are preserved after slow cryoprese...